Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Sleep Health|October 27, 2017
Delayed sleep phase disorder risk is associated with absenteeism and impaired functioningShantha M W Rajaratnam, Louis Licamele, Gunther Birznieks
Frontiers in Genetics|October 17, 2022
Case report: A novel missense variant in melanopsin associates with delayed sleep phenotype: Whole genome sequencing studySandra P Smieszek, Christos M Polymeropoulos, Gunther Birznieks, et al.
Plos One|September 19, 2025
Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trialNaoise C Synnott, Christos M Polymeropoulos, Changfu Xiao, et al.
Journal of Sleep Research|June 21, 2021
Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteonRosarelis Torres, Michaela Fisher, Gunther Birznieks, et al.
Clinical and Translational Gastroenterology|March 17, 2022
Enrichment of Motilin Receptor Loss-of-Function Variants in GastroparesisSandra P Smieszek, Jesse L Carlin, Changfu Xiao, et al.
Cytokine|February 5, 2022
Elevated plasma levels of CXCL16 in severe COVID-19 patientsSandra P Smieszek, Vasilios M Polymeropoulos, Christos M Polymeropoulos, et al.
Lancet (London, England)|December 5, 2008
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trialsShantha Mw Rajaratnam, Mihael H Polymeropoulos, Dennis M Fisher, et al.
The British Journal of Psychiatry : the Journal of Mental Science|May 9, 2025
Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trialYunsheng He, Christos M Polymeropoulos, Michael A Mohrman, et al.
Virology|May 22, 2022
Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infectionPrabhakaran Kumar, Manikannan Mathayan, Sandra P Smieszek, et al.
Frontiers in Neurology|October 3, 2022
Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trialChristos M Polymeropoulos, Vasilios M Polymeropoulos, Emily L Czeisler, et al.
Pageof 3